Expansion for range of cardiovascular genetic tests

Lab21 is to expand its portfolio of genetic tests for inherited cardiac syndromes.

Through its existing UK licence with PGxHealth, a division of Clinical Data, Inc., Lab21 offers exclusive UK and Ireland access to the Familion portfolio of tests for Long QT and Brugada Syndromes and has now added two new assays for catecholaminergic polymorphic ventricular tachycardia (CPVT) and hypertrophic cardiomyopathy (HCM) to its range of tests.
‘The addition of CPVT and HCM to the Familion stable substantially assists UK cardiologists in the accurate diagnosis of cardiac disease. By enabling cardiologists to quickly identify a patient’s risk, the most appropriate monitoring, treatment or lifestyle options can be implemented,’ explained Berwyn Clarke, Lab21 Chief Scientific and Development Officer at Lab21.

28.10.2008

News • Remote cardiology

A real-time telemonitoring device for heart failure patients

Medical monitoring tech company Umana Medical announced a collaboration with the Preventive Cardiology and Medical Prevention, Center of Cardiology at the University Medical Center Mainz and Bayer AG…

News • On the go

Improving wearables for medical applications

Cardiovascular diseases are the most common cause of fatalities in Germany. Medical wearables which measure vital parameters such as the blood pressure, heart rate and blood oxygen levels in real…

Article •

Trinity Biotech hits high mark for cardiac test

Ahead of regulatory approval that is expected before the end of the year, Trinity Biotech chose Medica to present the novel point-of-care (POC) analyzer Meritas with the Troponin I (TnI) that are…